Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Depreciation & Amortization (CF): 2015-2025

Historic Depreciation & Amortization (CF) for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $1.0 million.

  • Seres Therapeutics' Depreciation & Amortization (CF) fell 25.64% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 29.11%. This contributed to the annual value of $5.5 million for FY2024, which is 12.41% down from last year.
  • Seres Therapeutics' Depreciation & Amortization (CF) amounted to $1.0 million in Q3 2025, which was down 1.42% from $1.1 million recorded in Q2 2025.
  • Seres Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $1.7 million during Q3 2022, with a 5-year trough of $1.0 million in Q3 2025.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.4 million (2024), whereas its average is $1.4 million.
  • In the last 5 years, Seres Therapeutics' Depreciation & Amortization (CF) rose by 18.16% in 2022 and then tumbled by 33.52% in 2024.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Depreciation & Amortization (CF) stood at $1.6 million in 2021, then rose by 4.83% to $1.6 million in 2022, then grew by 0.31% to $1.6 million in 2023, then plummeted by 33.52% to $1.1 million in 2024, then decreased by 25.64% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.